【翰宇药业:利拉鲁肽注射液获FDA批准】翰宇药业公告,2024年12月23日,公司与Hikma联合申报的利拉鲁肽注射液新药简略申请已获得美国FDA批准证书。该药品为GLP-1类似物,具备促进胰岛素分泌、降低食欲等功能。此次获得FDA批准,意味着该药品可在美国合法销售,有助于公司与合作伙伴拓展美国市场,提升产品竞争力。目前,公司与Hikma已签署合同总额为4639.63万美元,折合人民币3.38亿元,正在积极履约中。

金融界
24 Dec 2024
翰宇药业公告,2024年12月23日,公司与Hikma联合申报的利拉鲁肽注射液新药简略申请已获得美国FDA批准证书。该药品为GLP-1类似物,具备促进胰岛素分泌、降低食欲等功能。此次获得FDA批准,意味着该药品可在美国合法销售,有助于公司与合作伙伴拓展美国市场,提升产品竞争力。目前,公司与Hikma已签署合同总额为4639.63万美元,折合人民币3.38亿元,正在积极履约中。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10